These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12145269)

  • 21. Glucagon-like peptide: a therapeutic glimmer.
    Amiel SA
    Lancet; 1994 Jan; 343(8888):4-5. PubMed ID: 7905051
    [No Abstract]   [Full Text] [Related]  

  • 22. Novel pharmacologic agents for type 2 diabetes.
    Uwaifo GI; Ratner RE
    Endocrinol Metab Clin North Am; 2005 Mar; 34(1):155-97. PubMed ID: 15752927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug Combo Adds No Benefit in Patients with Type 2 Diabetes.
    Geurin MD
    Am Fam Physician; 2016 Mar; 93(6):436-8. PubMed ID: 26977827
    [No Abstract]   [Full Text] [Related]  

  • 24. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
    Holst JJ; Deacon CF
    Diabetes; 1998 Nov; 47(11):1663-70. PubMed ID: 9792533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
    Sinclair EM; Drucker DJ
    Physiology (Bethesda); 2005 Oct; 20():357-65. PubMed ID: 16174875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical decisions. Management of type 2 diabetes.
    Goldberg RB; Holman R; Drucker DJ
    N Engl J Med; 2008 Jan; 358(3):293-7. PubMed ID: 18199869
    [No Abstract]   [Full Text] [Related]  

  • 27. ["Glucagon-like peptide I": a therapeutic alternative for diabetes mellitus?].
    Fehmann HC; Göke B
    Dtsch Med Wochenschr; 1994 Feb; 119(8):275-9. PubMed ID: 8112212
    [No Abstract]   [Full Text] [Related]  

  • 28. Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.
    Knudsen LB
    J Med Chem; 2004 Aug; 47(17):4128-34. PubMed ID: 15293981
    [No Abstract]   [Full Text] [Related]  

  • 29. [Modern antihyperglycaemic agents--what is the patient benefit?].
    Siegmund T
    MMW Fortschr Med; 2016 Apr; 158(7):45-8. PubMed ID: 27071585
    [No Abstract]   [Full Text] [Related]  

  • 30. Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent.
    Doyle ME; Greig NH; Holloway HW; Betkey JA; Bernier M; Egan JM
    Endocrinology; 2001 Oct; 142(10):4462-8. PubMed ID: 11564711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.
    Kannan S; Pantalone KM; Matsuda S; Wells BJ; Karafa M; Zimmerman RS
    J Diabetes; 2016 Mar; 8(2):279-85. PubMed ID: 25929426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
    Wang Y; Zhao L; Huang Q; Peng Y
    J Diabetes; 2014 Mar; 6(2):164-6. PubMed ID: 23879890
    [No Abstract]   [Full Text] [Related]  

  • 33. Which oral agent to use when metformin is no longer effective?
    Bannon M
    QJM; 2011 Mar; 104(3):183-4. PubMed ID: 21330402
    [No Abstract]   [Full Text] [Related]  

  • 34. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
    Nauck M
    Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Glucagon-like peptide-1(GLP-1)].
    Wasada T
    Nihon Rinsho; 2004 Jun; 62(6):1175-80. PubMed ID: 15206160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New pharmacological development (alpha glucosidase inhibitors, amylin analogues, GLP-1, thiozolidinediones, short acting insulin analogues).
    Dharmalingam M; Kumar P
    J Assoc Physicians India; 2001 Jan; 49 Spec No():46-9. PubMed ID: 11235605
    [No Abstract]   [Full Text] [Related]  

  • 37. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
    Nauck MA
    Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
    Lam NT; Kieffer TJ
    Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes.
    Kendall DM; Kim D; Maggs D
    Diabetes Technol Ther; 2006 Jun; 8(3):385-96. PubMed ID: 16800760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB; Madsbad S; Holst JJ
    Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.